miR-27b attenuates dexamethasone-inhibited proliferation and osteoblastic differentiation in MC3T3-E1 cells by

Huicheng Lv1, Tieyi Yang1, Aimin He1

  • 1Second Department of Trauma, Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010000, P.R. China.

Insights

MicroRNA-27b (miR-27b) protects against osteoporosis by enhancing osteoblast differentiation. It targets PPARγ2, counteracting dexamethasone

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • Osteoporosis is a prevalent metabolic bone disease with a high fracture risk, affecting millions globally.
  • MicroRNAs (miRNAs) are key regulators in osteoporosis pathogenesis.
  • miR-27b promotes osteoblastic differentiation, but its role in osteoporosis requires further investigation.

Purpose of the Study:

  • To investigate the mechanism of miR-27b in an in vitro osteoporosis model.
  • To determine if miR-27b targets peroxisome proliferator-activated receptor γ2 (PPARγ2).

Main Methods:

  • Established an in vitro osteoporosis model using MC3T3-E1 pre-osteoblasts treated with dexamethasone (DEX).
  • Utilized reverse transcription-quantitative PCR, western blotting, and dual-luciferase assays.
  • Employed miR-27b mimics and small interfering RNA (siRNA) for gene manipulation.

Main Results:

  • DEX treatment reduced cell viability and miR-27b expression.
  • miR-27b directly targeted and suppressed PPARγ2 expression.
  • Overexpression of miR-27b reversed DEX-induced inhibition of cell viability, alkaline phosphatase (ALP) activity, and osteoblastic markers (BMP2, Runx2, OCN).
  • miR-27b knockdown impaired osteoblast differentiation, an effect reversed by PPARγ2 silencing.

Conclusions:

  • miR-27b attenuates DEX-induced inhibition of proliferation and osteoblastic differentiation in pre-osteoblasts.
  • This protective effect is mediated through the direct targeting of PPARγ2.